Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001869248
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer Aerovate Therapeutics, Inc.

SEC File Number 001-40544

930 WINTER STREET

SUITE M-500

Address of Issuer WALTHAM MASSACHUSETTS

MASSACHUSEI IS

02451

Phone 617-443-2400

Name of Person for Whose Account the Securities are To Be Sold

Dake Benjamin T

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue 4th Floor New York NY 10022	56410	1506147.00	27670000	03/18/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	from Whom	this	Donor	Securities	Payment	Payment *

	Transaction	Acquired	a Acquired Gift?	l Acquired	
Common	04/02/2021 Options Grant	Aerovate Therapeutics, Inc.		12477	04/02/2021 N/A
Common	04/02/2021 Options Grant	Aerovate Therapeutics, Inc.		14933	04/02/2021 N/A
Common	12/14/2021 Options Grant	Aerovate Therapeutics, Inc.		29000	12/14/2021 N/A

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

All sales are to be made pursuant to a previously signed/adopted 10b5-1 selling plan dated 11/16/2023 and all representations regarding non-public information were made as of the

adoption of the plan.

Date of Notice 03/18/2024

Date of Plan Adoption or Giving

of Instruction, If Relying on Rule 11/16/2023

10b5-1

Remarks

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Benjamin Dake

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)